![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
EFFICACY AND SAFETY OF LONG-ACTING CABOTEGRAVIR + RILPIVIRINE IN
PARTICIPANTS WITH HIV/HCV CO-INFECTION: ATLAS-2M 48-WEEK RESULTS
|
|
|
Ronald D'Amico,1 Paul Benn,2 Shanker Thiagarajah,3 Susan Ford,4 Eileen Birmingham,5 Ojesh Upadhyay,6 Louise Garside,3 Rodica Van Solingen-Ristea,7 Kati Vandermeulen,7 William Spreen1
1ViiV Healthcare, Research Triangle Park, NC, USA; 2ViiV Healthcare, Brentford, United Kingdom; 3GlaxoSmithKline, Brentford, United Kingdom; 4GlaxoSmithKline, Research Triangle Park, NC, USA; 5Janssen Research and Development, Raritan, NJ, USA; 6GlaxoSmithKline, Collegeville, PA, USA; 7Janssen Research and Development, Beerse, Belgium
![1003211](../images/100421/100421-6/1003211.gif)
![1003212](../images/100421/100421-6/1003212.gif)
![1003213](../images/100421/100421-6/1003213.gif)
![1003214](../images/100421/100421-6/1003214.gif)
![1003215](../images/100421/100421-6/1003215.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|